Dasatinib

For research use only. Not for use in humans.

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

CAS No. 302962-49-8

Dasatinib (BMS-354825) 是一种新型有效的多靶点抑制剂,作用于AblSrcc-Kit,在无细胞试验中IC50分别为 <1 nM、0.8 nM 和 79 nM。Dasatinib 可诱导自噬和凋亡并具有抗肿瘤的活性。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
RMB 5487.3 现货
RMB 6691.23 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Dasatinib发表文献285篇:

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib (BMS-354825) 是一种新型有效的多靶点抑制剂,作用于AblSrcc-Kit,在无细胞试验中IC50分别为 <1 nM、0.8 nM 和 79 nM。Dasatinib 可诱导自噬和凋亡并具有抗肿瘤的活性。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NUfIZ446T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT4Umw4OiCq NHqwfnpFVVOR MVrJR|UxRTBwMECwNFch|ryP M1r0ZVE4QTV4MEiw
K562 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH6d5dNPzJiaB?= Mlz1SG1UVw>? NFOwc5BKSzVyPUCuNFAyKM7:TR?= M2iyWFE4QTV4MEiw
M07e M3P4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXUV4tPPzJiaB?= MVLEUXNQ MWjJR|UxRTBwMECxNkDPxE1? NIC5SZQyPzl3NkC4NC=>
ALL3 M{HVRmN6fG:2b4jpZ{BCe3OjeR?= NHjPSpMxNjIQvF2= M2exZVczKGh? MmixSG1UVw>? NXPhb|Z6UUN3ME2wMlAxODRizszN MXixPVg5QTV2MB?=
CML MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT3SZlVOjBibXnu MX3EUXNQ MnvTTWM2OD1yLkCwNUDPxE1? NVLPTI1lOTl{MUmwNVY>
BA/F3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLIO|IhcA>? NVvjPFc4TE2VTx?= NFuxc3pKSzVyPU[uOVg6KM7:TR?= MVGyN|A5QDZ2NB?=
BA/F3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TETFczKGh? M4i2N2ROW09? M3zDfGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN NUDGd2pUOjNyOEi2OFQ>
BA/F3 M3jHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT6bGZQPzJiaB?= NEDF[HFFVVOR NYXHTWJXUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= M17rdlI{ODh6NkS0
BA/F3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ftc|czKGh? M4jKO2ROW09? NXPoV4ZXUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN M4PFRlI{ODh6NkS0
BA/F3 M1WyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfUO|IhcA>? NHTpXYhFVVOR MX7JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? MlH2NlM{ODF5MEO=
BA/F3 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33lcVczKGh? NGLnfnpFVVOR M2f3TWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP NGmwZ2EzOzNyMUewNy=>
BA/F3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfS[ldyPzJiaB?= NUP3S4JoTE2VTx?= M{D6c2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP NVnNcWNwOjN|MEG3NFM>
BA/F3 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17BeVczKGh? NU\UZ5lzTE2VTx?= Mmj6TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? MYGyN|MxOTdyMx?=
BA/F3 NYP1dIJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi2fXJHPzJiaB?= MV;EUXNQ NX7VcFI3UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= NV\yeXJEOjN|MEG3NFM>
BA/F3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2npNFczKGh? NUKxSYVNTE2VTx?= NGfLTZdKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? M1LoflI{OzBzN{Cz
BA/F3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j0blczKGh? MmfYSG1UVw>? M3XzU2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP NVztbZVOOjN|MEG3NFM>
BA/F3 NUP5fpdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUS3NkBp NILkfllFVVOR M2Dud2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO M{jETVI{OzBzN{Cz
BA/F3 NIXvOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOzVmdTPzJiaB?= MXnEUXNQ MYrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? NFPTcmgzOzNyMUewNy=>
T cell MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDMU2M4OiCq MXfEUXNQ Mn7BTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> NH3GZmgyPzF3NEWxNi=>
WiDr NUjEUZdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\MNHhmPzJiaB?= MV\EUXNQ MnjkTWM2OD1yLkC1NkDPxE1? Mlf5NVU3OTV3MUK=
PC3 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHPO|IhcA>? M4rTdWROW09? M3:1TGlEPTB;MD6wNFk1KM7:TR?= Mn;uNVU3OTV3MUK=
MDA-MB-231 Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPGVHI4OiCq MYHEUXNQ NHPBdI9KSzVyPUCuNFEzKM7:TR?= NV[1To1DOTV4MUW1NVI>
Hs578T NXOyOYNPS3m2b4TvfIlkKEG|c3H5 M3PDVVczKGh? NHfEOmZFVVOR NVTvWlE{T0l3ME2wMlA{KM7:TR?= NVK2XGd[OjRyMUWzNlc>
HMEC MVfDfZRwfG:6aXOgRZN{[Xl? MoPrO|IhcA>? NGrmbXRFVVOR MUTHTVUxRTFwODFOwG0> M1XzSVI1ODF3M{K3
DU145 MYXDfZRwfG:6aXOgRZN{[Xl? M4XCXFczKGh? M2\uSmROW09? NGDnenFIUTVyPUCuNVYh|ryP MXKyOFAyPTN{Nx?=
U251 M2H5VGN6fG:2b4jpZ{BCe3OjeR?= MXW3NkBp M{fNUmROW09? NWnIWYdzT0l3ME2yMlgyKM7:TR?= NUnTcXY5OjRyMUWzNlc>
NCI60 Ml[4R5l1d3SxeHnjJGF{e2G7 NGrOeG44OiCq NFThU2tFVVOR NH3KbHJIUTVyPUWuO{DPxE1? M4rKTFI1ODF3M{K3
MALME-3M NFG1e|VEgXSxdH;4bYMhSXO|YYm= NEnx[lc4OiCq NFfWOlBFVVOR NYO4[ZBqT0l3ME22MlYyKM7:TR?= MWmyOFAyPTN{Nx?=
KM12 M{PyXWN6fG:2b4jpZ{BCe3OjeR?= M3jTWVczKGh? MW\EUXNQ NYjJS2Z4T0l3ME23MlQ1KM7:TR?= MnHTNlQxOTV|Mke=
SW620 NUD0N|k1S3m2b4TvfIlkKEG|c3H5 MUC3NkBp MYfEUXNQ MVzHTVUxRThwNEOg{txO M3nwNlI1ODF3M{K3
RXF 393NL MojiR5l1d3SxeHnjJGF{e2G7 MlK2OEBl[Xm| MlX6SG1UVw>? MWPJR|UxRTBwMEKxO{DPxE1? NGX5bWUzOzJ3M{C3OC=>
LXFA 983L NXnPbY9tS3m2b4TvfIlkKEG|c3H5 MW[0JIRigXN? MV3EUXNQ MlTNTWM2OD1yLkC1OlUh|ryP MmnnNlMzPTNyN{S=
PRXF DU145 MorKR5l1d3SxeHnjJGF{e2G7 MYG0JIRigXN? NGDY[m5FVVOR Mnz2TWM2OD1yLkC2NlMh|ryP NYmwZ5ZxOjN{NUOwO|Q>
PAXF 1657L NHvicGtEgXSxdH;4bYMhSXO|YYm= NFH4NYM1KGSjeYO= M{TyeWROW09? M{XUdGlEPTB;MD6xNlEh|ryP NIPjR4MzOzJ3M{C3OC=>
CXF 1103L NVHEfZZMS3m2b4TvfIlkKEG|c3H5 M{XZPFQh\GG7cx?= MXvEUXNQ NEK3R4VKSzVyPUSuN|Yh|ryP M1H1fFI{OjV|MEe0
GXF251L NV\qN4x1S3m2b4TvfIlkKEG|c3H5 NHvHN|Y1KGSjeYO= MkLOSG1UVw>? MoTYTWM2OD1{LkK1JO69VQ>? M32yZVI{OjV|MEe0
NCI-H23 NGDle2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmzRYY4OiCq M36ySWROW09? NYPWVWc5UUN3ME2yMlI4KM7:TR?= Mn3BNlM2OjFyMkC=
HCT116 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVO3NkBp Ml7aSG1UVw>? M13OZmlEPTB;Mj6zJO69VQ>? M4H3[|I{PTJzMEKw
MCF7 NFLVPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPQT5A4OiCq MlTPSG1UVw>? MkfzTWM2OD1{LkW3JO69VQ>? M4TG[|I{PTJzMEKw
NCI-H460 M3TmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInjR4U4OiCq NEPHfm5FVVOR NVv1cIp4UUN3ME24Mlk6KM7:TR?= M4XTWVI{PTJzMEKw
DLD1 M3zDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG3NkBp NGDKSG5FVVOR MUHJR|UxRTRwNjFOwG0> NVrTRYhEOjN3Nke5OlA>
NCI-H661 M{jCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq5ZYc4OiCq MYTEUXNQ MVTJR|UxRTdwODFOwG0> NI[1TGczOzV4N{m2NC=>
A549 MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwUVczKGh? M2W5e2ROW09? Ml:zTWM2OD16LkKg{txO MU[yN|U3Pzl4MB?=
U937 NFLNOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rR[VczKGh? MmXZSG1UVw>? MnLYTWM2OD1zMj6yJO69VQ>? NVXSZmNYOjN3Nke5OlA>
HEK293 NGfZdYdHfW6ldHnvckBCe3OjeR?= NXP6S29rOTEEoN88US=> Mm[1SG1UVw>? MV;JcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= Mn:xNlI4PzB4MUC=
HUVEC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e4OFAvOTYEoN88US=> MnS1O|IhcA>? MVrEUXNQ NHu1fohKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> MWKyNlg2Ozl7Mx?=
HUVEC NV\WNIhQTnWwY4Tpc44hSXO|YYm= NHHHcoYyPcLizszN M1jPOVczKGh? MWLEUXNQ M1S3Zmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO NFXkcWQzOjh3M{m5Ny=>
Plasmodium falciparum MoTUSpVv[3Srb36gRZN{[Xl? MorRNVDDqM7:TR?= M{HrbFE2KG2rbh?= M1T5OmROW09? NHLDTHdKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? NUjve|VXOjR3NUCzN|A>
PC3 MkHPSpVv[3Srb36gRZN{[Xl? MXKwMlEh|ryP NYq1b3JRPSCq NGXDXmxFVVOR M3[5OGlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= M3zuTVE6PDZ{OUe1
DU145 MUHGeY5kfGmxbjDBd5NigQ>? MlO2NE4yKM7:TR?= Mnq0OUBp M36yZWROW09? MoHKTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= M3fKclE6PDZ{OUe1
PC3 NYnNb4pRU2mwYYPlJGF{e2G7 NHPGU2MxNjFizszN M{jQeVUhcA>? Mon5SG1UVw>? NVLCUHl6UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MVOxPVQ3Ojl5NR?=
DU145 NWfFb4hvU2mwYYPlJGF{e2G7 MlPiNE4yKM7:TR?= MXy1JIg> MlT0SG1UVw>? MYDJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= NES5V3EyQTR4Mkm3OS=>
PC3 NGLKUoFMcW6jc3WgRZN{[Xl? MVqwMlEh|ryP M3XzflUhcA>? MmXOSG1UVw>? MUHJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> MlG2NVk1PjJ7N{W=
DU145 NXjMd|hOU2mwYYPlJGF{e2G7 M2fSe|AvOSEQvF2= NEW3dlk2KGh? MnTHSG1UVw>? M2rY[GlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P MoDKNVk1PjJ7N{W=
Huh7 NVTxPGhCSW62aY\pdoFtKEG|c3H5 M2HmRlIvPSEQvF2= MVm0JIRigXN? NFThNG5FVVOR MYXJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MWKxO|M3ODZ5Nh?=
C6/36 NIHmZYZCdnSrdnnyZYwhSXO|YYm= NF;1bHkzNjVizszN Mle5OEBl[Xm| NVjMWmpqTE2VTx?= NFPMT5FKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP NILQe5YyPzN4ME[3Oi=>
U937 NH[1VmFHfW6ldHnvckBCe3OjeR?= MW[xJO69VQ>? NYX6dFh[OSCq NXLYbVRDTE2VTx?= NGH1dVFT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= NVjOUotwOTd4OESwPVk>
U937 MlHrSpVv[3Srb36gRZN{[Xl? NFfGbHIyKM7:TR?= MojTNUBp Mof0SG1UVw>? M3vWXHJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ NWXxeI5lOTd4OESwPVk>
murine mast cell MX7GeY5kfGmxbjDBd5NigQ>? Ml2wNUDPxE1? M2PKdFI1KGh? MW\EUXNQ M4DMZWlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP MoKwNVc3QDRyOUm=
BV-173 NFjRfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\1UWlEPTB;MD6wNFAxODBzMEmg{txO MonVV2FPT0WU
K-562 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUntXYFiUUN3ME2wMlAxODByMEK2OkDPxE1? NYXZNmc3W0GQR1XS
BL-70 NUPDVWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vRdWlEPTB;MD6wNFAxODB6MkKg{txO NEjEfldUSU6JRWK=
EM-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[0dWlEPTB;MD6wNFAxODFyODFOwG0> NETEc2VUSU6JRWK=
LAMA-84 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zERmlEPTB;MD6wNFAxODN{MTFOwG0> NUfPZZpFW0GQR1XS
MEG-01 NFmzTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuxWHZoUUN3ME2wMlAxODByOUig{txO M3raXXNCVkeHUh?=
EoL-1-cell NGP0b|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDHSHFtUUN3ME2wMlAxODBzM{Gg{txO M1SzSHNCVkeHUh?=
CTV-1 M{LBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XCR2lEPTB;MD6wNFAxPDB2IN88US=> MlnDV2FPT0WU
TE-15 NH;DfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPnTWM2OD1yLkCwOVg6KM7:TR?= NUXscnpzW0GQR1XS
NOS-1 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LnNGlEPTB;MD6wNFYyOyEQvF2= MVLTRW5ITVJ?
D-336MG MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMEC2N{DPxE1? M4LZVXNCVkeHUh?=
LB1047-RCC NV;T[nRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEC5PFkh|ryP Mne1V2FPT0WU
LB996-RCC NYC0PJk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInrdYNKSzVyPUCuNFA6QTFizszN NYfTb5dsW0GQR1XS
SW982 NYW2VYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5TWM2OD1yLkCxNVE2KM7:TR?= MmrFV2FPT0WU
TK10 M3G5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1La[WlEPTB;MD6wNVE4PCEQvF2= MnzZV2FPT0WU
A704 NVP4T2syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEG0PVEh|ryP NHPZRlhUSU6JRWK=
TE-8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILxcpVKSzVyPUCuNFE2PzZizszN MmPXV2FPT0WU
DOHH-2 M{XRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fPTGlEPTB;MD6wNVcyQSEQvF2= NIDkdY5USU6JRWK=
HOP-62 NW[3b5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEG4N|Qh|ryP Ml3GV2FPT0WU
TE-12 M3;ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEG4OlEh|ryP MlXaV2FPT0WU
KGN MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TlWWlEPTB;MD6wNVk1OiEQvF2= NYPUNGZoW0GQR1XS
NCI-H1648 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW4T4dKSzVyPUCuNFIxOTFizszN NFHFbllUSU6JRWK=
OS-RC-2 M{jYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\3ZmlEPTB;MD6wNlA{KM7:TR?= MmrSV2FPT0WU
GB-1 Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7iTWM2OD1yLkCyNVU4KM7:TR?= Ml\UV2FPT0WU
RXF393 NYG0foRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG0W5hKSzVyPUCuNFI{PTdizszN NUPjcXlxW0GQR1XS
LC-2-ad MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnCVWVxUUN3ME2wMlAzPTh4IN88US=> NF\nXZJUSU6JRWK=
KS-1 M1[ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLUTWM2OD1yLkCyO|Mh|ryP MljPV2FPT0WU
ETK-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTSWXVKSzVyPUCuNFI5OzJizszN MkjnV2FPT0WU
SW954 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXnTWM2OD1yLkCyPVI4KM7:TR?= NIfWeVlUSU6JRWK=
Becker M172XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK0dXNKSzVyPUCuNFMxODNizszN MVnTRW5ITVJ?
MZ1-PC NYTYS2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NICyd4dKSzVyPUCuNFMyOTlizszN NV75T3RmW0GQR1XS
ES6 M{\6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:2TWM2OD1yLkCzNVk{KM7:TR?= MlfQV2FPT0WU
KURAMOCHI M2XnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2z[FhKSzVyPUCuNFM1QDdizszN NHH2eIdUSU6JRWK=
CGTH-W-1 M4DXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWzSldKSzVyPUCuNFM2PDhizszN M4\RcnNCVkeHUh?=
VA-ES-BJ NWnhWHFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjXdHlCUUN3ME2wMlA{QTB{IN88US=> NIXlSXpUSU6JRWK=
LXF-289 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEO5OVYh|ryP NHnIdGNUSU6JRWK=
MPP-89 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TBd2lEPTB;MD6wOFA1QSEQvF2= M3jnbHNCVkeHUh?=
SW872 NXn5[ZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\MTWM2OD1yLkC0NVYyKM7:TR?= MXXTRW5ITVJ?
SNB75 NFLvO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHKUphiUUN3ME2wMlA1PDN3IN88US=> Mm\pV2FPT0WU
PSN1 M{LWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml34TWM2OD1yLkC0OFc1KM7:TR?= NW\FWYUyW0GQR1XS
LB831-BLC M1fCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonmTWM2OD1yLkC0OlA6KM7:TR?= MoDCV2FPT0WU
MFH-ino MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHN[GxKSzVyPUCuNFQ4OjRizszN NInIOZVUSU6JRWK=
TGBC24TKB M13hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMES3OlEh|ryP MV7TRW5ITVJ?
A388 M3rX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\aRpJKSzVyPUCuNFUxQTVizszN NGHSWXNUSU6JRWK=
BB30-HNC NV6z[FlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHMe4lKSzVyPUCuNFU1OzdizszN NWnYWHIzW0GQR1XS
GI-ME-N MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi2VZJrUUN3ME2wMlA3OTF6IN88US=> MnnrV2FPT0WU
TGBC1TKB NUfvZ3JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\pZ|RPUUN3ME2wMlA3OTZ2IN88US=> NX[3dYhOW0GQR1XS
TE-10 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHTd|ZKSzVyPUCuNFY{PTdizszN MnjDV2FPT0WU
A498 M1TlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\2bmlEPTB;MD6wO|I5PCEQvF2= M1r4RnNCVkeHUh?=
TE-11 NX3iWYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDiTWM2OD1yLkC3PFU5KM7:TR?= MkHiV2FPT0WU
BB65-RCC NI\CUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHsTWM2OD1yLkC4NlI4KM7:TR?= MUHTRW5ITVJ?
C2BBe1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPRTWM2OD1yLkC4N|A5KM7:TR?= NV7qdGpYW0GQR1XS
NCI-H747 NXvGNmpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37WSWlEPTB;MD6wPFM3OiEQvF2= MVTTRW5ITVJ?
IST-MES1 NIKyWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITCeFRKSzVyPUCuNFg2PTJizszN NH\v[oNUSU6JRWK=
KALS-1 M2TkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vSb2lEPTB;MD6wPVQ6KM7:TR?= NET2W2RUSU6JRWK=
GCIY MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rT[WlEPTB;MD6wPVY2PiEQvF2= NFjQdpVUSU6JRWK=
RL95-2 M1e2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vrR2lEPTB;MD6xNFM5KM7:TR?= Mkm4V2FPT0WU
TE-1 NX3QSVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[zb2lEPTB;MD6xNFU1KM7:TR?= NFXVNmFUSU6JRWK=
NCI-H1355 NYfzUlQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\XWXdvUUN3ME2wMlEyODJ6IN88US=> NFTZSYtUSU6JRWK=
SW962 NELwbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfqXIhKSzVyPUCuNVEzQTJizszN MUjTRW5ITVJ?
KLE NH\0cFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLhTWM2OD1yLkGxN|E4KM7:TR?= M322V3NCVkeHUh?=
MC116 NXPrZZBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLoT2hIUUN3ME2wMlEyPDFizszN M4\Zb3NCVkeHUh?=
NMC-G1 NGLZVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHsNXMzUUN3ME2wMlEyPjB4IN88US=> NEWzWZNUSU6JRWK=
KU812 MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMUG4PFMh|ryP NUjoO|hnW0GQR1XS
COLO-829 NX;CZmh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknJTWM2OD1yLkGyNlE{KM7:TR?= MW\TRW5ITVJ?
NTERA-S-cl-D1 NIPWSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;HeGlEPTB;MD6xNlI5OyEQvF2= Ml2wV2FPT0WU
IST-MEL1 NYPMeIFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMUO0OUDPxE1? MXjTRW5ITVJ?
MLMA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUSwN|Ih|ryP M3HCb3NCVkeHUh?=
LS-123 M3[zcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHhT3NUUUN3ME2wMlE1ODZ2IN88US=> NW\VNnU6W0GQR1XS
LB2518-MEL M2m5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzzTWM2OD1yLkG0NVYzKM7:TR?= NH\Xb5BUSU6JRWK=
NB69 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTxWllKSzVyPUCuNVQ1OzZizszN MV\TRW5ITVJ?
8-MG-BA NHu4cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLlfVBHUUN3ME2wMlE2PDV6IN88US=> NH7mXZZUSU6JRWK=
K5 M2jrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GyZWlEPTB;MD6xOlQ5QSEQvF2= NFz5N2hUSU6JRWK=
KINGS-1 NWnmT4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULFXY1qUUN3ME2wMlE3PjZ4IN88US=> NWC0PJhbW0GQR1XS
SF268 M{fpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj4TWM2OD1yLkG3OFA1KM7:TR?= NETiPIFUSU6JRWK=
PF-382 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjkZplKSzVyPUCuNVc3PzhizszN NGTWcVZUSU6JRWK=
SH-4 NIXsTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMUi0NVMh|ryP NXrRdIRIW0GQR1XS
NALM-6 NX\5cINiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMUmyPVUh|ryP M2XxfHNCVkeHUh?=
CP66-MEL NEPuNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTjOYt3UUN3ME2wMlE6PTNzIN88US=> NXz2bGZQW0GQR1XS
697 NYTkeHVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DXdmlEPTB;MD6xPVk5PyEQvF2= MlzTV2FPT0WU
CP67-MEL MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzzcHRvUUN3ME2wMlIxPDh6IN88US=> NWKxV3NiW0GQR1XS
DSH1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMkSwNFEh|ryP M4raSHNCVkeHUh?=
HCE-4 NXnYS5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXFTWM2OD1yLkK2OFM6KM7:TR?= M3fXV3NCVkeHUh?=
MZ2-MEL M1j6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;YTWM2OD1yLkK4OVM4KM7:TR?= NF3Fe|ZUSU6JRWK=
BL-41 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfUSW5bUUN3ME2wMlI6OTJ|IN88US=> NWDNWlBVW0GQR1XS
HUTU-80 M{L1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwM{G0NkDPxE1? M3Lr[HNCVkeHUh?=
LOXIMVI Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfMV3FKSzVyPUCuN|E2ODNizszN NWPNeJRQW0GQR1XS
no-10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwM{G5N|Eh|ryP NVXVb40xW0GQR1XS
KARPAS-422 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwM{O5PVch|ryP M4PuTnNCVkeHUh?=
SW684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXhOmhqUUN3ME2wMlM1QThizszN MlzDV2FPT0WU
SF126 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofjTWM2OD1yLkO1OFEh|ryP NGfTcoNUSU6JRWK=
D-263MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPZTWM2OD1yLkO2NlI1KM7:TR?= MWXTRW5ITVJ?
OVCAR-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm3OJlKSzVyPUCuN|c1OzNizszN NFLaW4ZUSU6JRWK=
BB49-HNC MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmezTWM2OD1yLkO4OVk6KM7:TR?= NUXBU2ZIW0GQR1XS
ONS-76 NVrM[WlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fJUWlEPTB;MD60Nlk2OSEQvF2= MmPxV2FPT0WU
MZ7-mel NEfxbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjVTWM2OD1yLkS3PVEyKM7:TR?= NIHTTZlUSU6JRWK=
RCC10RGB NYDQflBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ZfJJKSzVyPUCuOFkyOSEQvF2= NFyxXINUSU6JRWK=
BOKU MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\NT2lEPTB;MD60PVE{OyEQvF2= NIrVW4ZUSU6JRWK=
no-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;hTWM2OD1yLkWwNlI5KM7:TR?= MYHTRW5ITVJ?
IST-SL2 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrHTGFjUUN3ME2wMlUxOzB{IN88US=> NXXNboY4W0GQR1XS
RKO NUmwSXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nTemlEPTB;MD61Nlk3PiEQvF2= MmS2V2FPT0WU
HT-144 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:5c2lpUUN3ME2wMlU{PjB7IN88US=> NVT1e2RSW0GQR1XS
NCI-H446 NUn6SWIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DtbmlEPTB;MD62Nlc3KM7:TR?= NXv3U4hPW0GQR1XS
QIMR-WIL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDac3p3UUN3ME2wMlcxPjJ7IN88US=> MlXOV2FPT0WU
MHH-PREB-1 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwN{S0Olkh|ryP NGHvXJBUSU6JRWK=
EW-16 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwN{[xO|gh|ryP M4DlR3NCVkeHUh?=
EW-24 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjIXnJ1UUN3ME2wMlc5OTZ3IN88US=> MWjTRW5ITVJ?
LB373-MEL-D MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHvVZdKUUN3ME2wMlgzPTB6IN88US=> MnG2V2FPT0WU
TE-9 NF\weXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7EfnZKSzVyPUCuPFc2OzJizszN NX7xWZZmW0GQR1XS
A3-KAW NWCyNpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\HeGlEPTB;MD65PFQ2OiEQvF2= MVrTRW5ITVJ?
A101D NILTToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXvcppSUUN3ME2xMlA{ODR|IN88US=> MmXNV2FPT0WU
OCUB-M MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnhT29KSzVyPUGuNFQ1OTJizszN MlTRV2FPT0WU
ES4 M{P3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILXXJVKSzVyPUGuNFUyPDVizszN M3Ppd3NCVkeHUh?=
TE-6 NXTDdHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnGbI8yUUN3ME2xMlIyOjJ4IN88US=> NV\JTI4xW0GQR1XS
D-502MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPmTWM2OD1zLkKzN|c3KM7:TR?= NVPlZWI4W0GQR1XS
KNS-42 NWHobYp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv4VJh1UUN3ME2xMlI1PDF{IN88US=> MWPTRW5ITVJ?
SNU-C2B M1G3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrmWWtKSzVyPUGuN|A2QDlizszN MoHpV2FPT0WU
NCI-H1838 NGHVcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPjV29bUUN3ME2xMlMxPzN|IN88US=> M4fHZXNCVkeHUh?=
NKM-1 NGK0S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\6TWM2OD1zLkOwPFU6KM7:TR?= NHmwSmpUSU6JRWK=
GI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLjOnpKSzVyPUGuN|YzOiEQvF2= M4jnOHNCVkeHUh?=
NB5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmzSFVKSzVyPUGuN|k5OjdizszN MUfTRW5ITVJ?
CAS-1 NVnYRplbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXWSohKSzVyPUGuOFA6QTJizszN M1zZeHNCVkeHUh?=
HCE-T M{HkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7VdlZKSzVyPUGuOVY4OTRizszN NFj1TppUSU6JRWK=
SBC-1 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwNUe5PFQh|ryP NFPUeGRUSU6JRWK=
JiyoyeP-2003 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L1PWlEPTB;MT63N|Q3PiEQvF2= MWjTRW5ITVJ?
TE-5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uzXWlEPTB;MT63PVE{QSEQvF2= NVj5NpBNW0GQR1XS
CAN Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjnR4Z1UUN3ME2xMlgzOjV{IN88US=> MYrTRW5ITVJ?
SK-UT-1 NXW3elc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTqdmFsUUN3ME2yMlE3Pjl|IN88US=> MlTVV2FPT0WU
JVM-2 M2\3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O1eWlEPTB;Mj6zOlI5PCEQvF2= MUTTRW5ITVJ?
LB771-HNC NYfsVmdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny3TWM2OD1{LkW3OVUyKM7:TR?= MW\TRW5ITVJ?
NCCIT M2q5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DvU2lEPTB;Mj64OlYyPiEQvF2= MUfTRW5ITVJ?
NCI-H2126 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jld2lEPTB;Mj64O|U2OiEQvF2= MWDTRW5ITVJ?
Calu-6 M1G3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS5XnJKSzVyPUOuNFU4PDFizszN NFfYNXRUSU6JRWK=
SK-LMS-1 M3XYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nmWWlEPTB;Mz6xNVg5PiEQvF2= NYTl[WFZW0GQR1XS
ARH-77 NIHmcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn62TWM2OD1|LkS2PVE2KM7:TR?= NIDTV5hUSU6JRWK=
NB17 NGrVbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNwNkO4OFch|ryP M3vqN3NCVkeHUh?=
A253 NHjVPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnVSHZKSzVyPUOuO|MzPDZizszN MYTTRW5ITVJ?
OPM-2 M4nEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS2dmQ3UUN3ME20MlI4Pjh3IN88US=> M1TBWHNCVkeHUh?=
MV-4-11 M2jON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzhU3ZKSzVyPUSuN|Y1PTRizszN NXr4b|hJW0GQR1XS
SR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xle2lEPTB;ND60PVk2PCEQvF2= MYXTRW5ITVJ?
KG-1 NH62VJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\MN49KSzVyPUSuOlA5PDVizszN NInrTYJUSU6JRWK=
OCI-AML2 NUHzd4c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH5WlVKSzVyPUWuPFYyPTRizszN NXr4boFZW0GQR1XS
D-247MG M4DoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\m[GJiUUN3ME22MlEzPTF7IN88US=> Ml7iV2FPT0WU
DJM-1 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTqWVF{UUN3ME22MlQ5PTV6IN88US=> NFTXUIRUSU6JRWK=
RPMI-6666 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WyW2lEPTB;Nz6yO|A3PyEQvF2= M1uyW3NCVkeHUh?=
KARPAS-45 NVuxfZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\UXGlEPTB;Nz61NVY4OSEQvF2= M4HGSXNCVkeHUh?=
LP-1 M3H6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L5fGlEPTB;Nz61OFc5OiEQvF2= M2PweXNCVkeHUh?=
RS4-11 NETNNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi2c5pKSzVyPUeuOlU4QDdizszN M2LIbnNCVkeHUh?=
DU-4475 NU\nT2hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr6botKSzVyPUiuNlE3PTJizszN M1noUHNCVkeHUh?=
MONO-MAC-6 NXPROW9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M162d2lEPTB;OD6yO|A3PiEQvF2= NYPzR4xCW0GQR1XS
NCI-SNU-16 M3\PZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTqTWM2OD16LkW2NVI5KM7:TR?= NFy2V5dUSU6JRWK=
SJSA-1 NHL0d4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrRRoJKSzVyPUiuO|I5ODVizszN NGPQTWdUSU6JRWK=
MMAC-SF NX[1R|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn76TWM2OD16Lke5N|A4KM7:TR?= MX7TRW5ITVJ?
SK-NEP-1 NGS3cIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRThwOEmxOVUh|ryP NFjT[3NUSU6JRWK=
J-RT3-T3-5 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrmclFKSzVyPUiuPVY2OjlizszN NF;i[3pUSU6JRWK=
SKM-1 NVi5eWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDzcpNKSzVyPUmuNFE4OzRizszN NVL0e2NPW0GQR1XS
LB2241-RCC M3K5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHZTVhKSzVyPUmuNFIxOTJizszN M16yTnNCVkeHUh?=
SIG-M5 NFqzN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC5WZdKSzVyPUmuNFI1QTNizszN Mom0V2FPT0WU
EVSA-T MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CwO2lEPTB;OT6yO|c6OyEQvF2= M3PsenNCVkeHUh?=
GT3TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\CTWlEPTB;OT6zOVU1PiEQvF2= MlvYV2FPT0WU
NB6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjnTWM2OD17LkmyNlU6KM7:TR?= MoX4V2FPT0WU
EHEB MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXWfYRKSzVyPUGwMlA3PTZizszN NHno[5NUSU6JRWK=
HEL NWK2[WgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXaeXpjUUN3ME2xNE41Pzd4IN88US=> MnPTV2FPT0WU
ALL-PO MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW3eYt3UUN3ME2xNE44QTN6IN88US=> MVfTRW5ITVJ?
TGW MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2flfmlEPTB;MUGuNlgzQCEQvF2= NWTpb2tnW0GQR1XS
BC-3 NFTLdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLheVJYUUN3ME2xNk4yOTN6IN88US=> MnPMV2FPT0WU
IA-LM M{LTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF{LkS0OFUh|ryP Ml:wV2FPT0WU
UACC-257 M3X0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4njOGlEPTB;MUKuPVE6QCEQvF2= MXnTRW5ITVJ?
KP-N-YS NIr4S3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF{LkmyPFMh|ryP M3i4N3NCVkeHUh?=
Raji M4rhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uwU2lEPTB;MUOuO|Q6PyEQvF2= MnjaV2FPT0WU
SF539 M2\jN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\UT5pJUUN3ME2xN{45PTV5IN88US=> NFP0fVFUSU6JRWK=
DMS-153 NF3YZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\YTIVIUUN3ME2xOE4xODJ6IN88US=> MnnwV2FPT0WU
L-540 NULVcnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF3LkC2O|Ih|ryP NWfmWHEyW0GQR1XS
MN-60 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHyWGFKSzVyPUG1MlE6PzlizszN Mn3rV2FPT0WU
RPMI-8866 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17hdmlEPTB;MUeuOFQ2PCEQvF2= MVrTRW5ITVJ?
NCI-H510A NYjwZpJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXBTWM2OD1zOT6zPVc{KM7:TR?= NHXxZVhUSU6JRWK=
NB13 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TmbmlEPTB;MUmuOFg4PyEQvF2= NYj2d2VwW0GQR1XS
HAL-01 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPUU4RVUUN3ME2xPU44PTR|IN88US=> MV7TRW5ITVJ?
NCI-H720 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJyLkK3N|Mh|ryP NYjV[2dPW0GQR1XS
REH MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;MfZJKSzVyPUKwMlY{PTdizszN MoDnV2FPT0WU
KNS-81-FD MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XLV2lEPTB;MkOuNVQ3KM7:TR?= MmL2V2FPT0WU
HC-1 NGG4RYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ2LkW1OVEh|ryP NX\DVIhMW0GQR1XS
NCI-H2141 NU[0OZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LjRmlEPTB;MkSuO|c2PCEQvF2= NInlTGNUSU6JRWK=
MOLT-4 M33o[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn1VIhKSzVyPUK2MlY4PTNizszN MmnjV2FPT0WU
OMC-1 NX7UVWgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ5LkG0NlIh|ryP NU\kfWN6W0GQR1XS
LC-1F NEPyW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHIZm1KSzVyPUK3MlMzPDVizszN NFPLS4NUSU6JRWK=
NCI-H1304 M1ni[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ6LkG2Nlgh|ryP NXLPTmhGW0GQR1XS
BC-1 NEL0UpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPWRVRPUUN3ME2yPE43PTFizszN NX\LVYhmW0GQR1XS
NCI-H64 NIPEO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ7Lk[yOVMh|ryP MWrTRW5ITVJ?
MOLT-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSxN3VRUUN3ME2yPU43Ojl{IN88US=> NWC3U2FpW0GQR1XS
U-87-MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vmS2lEPTB;M{CuO|Y3KM7:TR?= NGniWGdUSU6JRWK=
GAK Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fXPWlEPTB;M{GuNlY5PiEQvF2= MnnMV2FPT0WU
ES8 NETNNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nKb2lEPTB;M{KuNVI2OiEQvF2= NILKSWxUSU6JRWK=
HCC1599 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2wRYxXUUN3ME2zNk4{OzJ3IN88US=> MnPJV2FPT0WU
EB-3 NVvJNHZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1dHZ3UUN3ME2zOE4{OTF5IN88US=> MYHTRW5ITVJ?
HCC1187 NF7oR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjjflJYUUN3ME2zOU45ODV{IN88US=> MX\TRW5ITVJ?
SK-PN-DW Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32wVWlEPTB;M{[uNVk1OyEQvF2= Mlv3V2FPT0WU
JVM-3 MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrVfFlKSzVyPUO3MlI{OzhizszN M2PrVXNCVkeHUh?=
HCC2157 M3v6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDvZm1KSzVyPUO3Mlk6PDZizszN NGXz[JFUSU6JRWK=
A4-Fuk MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jLRmlEPTB;M{iuNVAxQSEQvF2= NGTG[ZFUSU6JRWK=
COR-L279 M1XGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRyLkK4OVEh|ryP MU\TRW5ITVJ?
DEL NFzVcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTNZZhzUUN3ME20NU46ODh4IN88US=> MkLUV2FPT0WU
NCI-H1395 NUDhZ4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzCUmlKSzVyPUSyMlAyPjNizszN MnP4V2FPT0WU
MHH-NB-11 NWi5RpMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7CTGZKSzVyPUSzMlA5OThizszN NHuzb29USU6JRWK=
NCI-H2107 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTL[4dKSzVyPUSzMlQ5PDZizszN NH6xcpZUSU6JRWK=
NEC8 NGi2[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\vTWM2OD12ND6zN|Yh|ryP NXvtZ4JkW0GQR1XS
COLO-684 NXLIb2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nrO2lEPTB;NE[uNlI2QCEQvF2= MWLTRW5ITVJ?
LS-411N NXzqUG1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm2b3dKSzVyPUS4MlQ4PDhizszN NHW3UXdUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
- 合并
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
储存条件 粉状
溶于溶剂
别名 BMS-354825

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Recruiting Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic February 14 2020 Phase 1|Phase 2
NCT04155411 Recruiting Drug: Dasatinib Dasatinib|BCR-ABL|Chronic Myeloid Leukemia Shenzhen Second People''s Hospital December 1 2019 Phase 4
NCT04115059 Recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 4 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID